This report highlights the need for close surveillance of bioprosthetic valves.
| INTRODUCTION
Failure of bioprosthetic heart valves commonly occurs late after implantation and is typically due to gradual calcific degeneration of valve leaflets. 1 In contrast, early deterioration of bioprosthetic valves is rare, and risk factors for this occurrence have not been completely uncovered. 2 Here, we present an unusual case of early calcific degeneration of the Epic bioprosthetic valve (St. Jude Medical, St. Paul, MN) in the aortic position less than 2 years after implantation.
| CASE REPORT
This is the case of a 69-year-old lady with normal renal function and who receives neither regular medications nor dietary supplements. This patient had undergone elective aortic valve replacement 20 months before for a severe degenerative aortic valve stenosis. A 19-mm Epic bioprosthetic valve had been implanted due to the small aortic annulus, and immediate postoperative echocardiography had confirmed an estimated mean gradient across the bioprosthetic valve of 11 mm Hg and an effective valve orifice area of 1.6 cm 
| COMMENT
The Epic stented porcine bioprosthetic aortic valve has been associated with low percentages of structural failure.
1 Beside the present case, only one prior report of early degeneration of the Epic valve appears in the medical literature. 2 The primary pathology accounting for bioprosthetic valve failure is leaflet calcification and stiffening, resulting in valve degeneration.
| IZZAT eT Al.
A variety of factors is known to induce leaflet calcification, mainly high serum calcium levels, vitamin D and calcium supplementations, chronic renal failure, and hemodialysis. 3 Glutaraldehyde pretreatment has also been implicated in bioprosthetic valve degeneration. A reaction of membraneattached phosphorus with calcium-loaded extracellular fluid can form phosphate-calcium mineral deposits and could possibly initiate leaflet calcification. 4 Another hypothesis is that glutaraldehyde fixation may not eliminate the antigenicity of bioprosthetic tissues fully, and that xenograft rejection and consequential calcification may be a reason for bioprosthetic valve failure. 5 Leaflet calcific degeneration tends to progress slowly in old patients but is noticeably accelerated in younger subjects, and the process underlying this effect of age is still uncertain. 4 None of the aforementioned risk factors for leaflet calcification were present in our patient; hence, early degeneration of this Epic valve under seemingly benign settings remains unaccountable. Since transcatheter aortic valve replacement (TAVR) is still not available in our country, we felt it was prudent to replace the degenerate valve, and we elected to use a mechanical prosthesis to preclude a second bioprosthetic valve failure, even though other physicians may contest this notion.
Even though early bioprosthetic valve failure remains infrequent, reporting such incidents is warranted to help recognize the mechanisms underlying early degeneration of bioprosthetic heart valves. 
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